Compare Goodyear Tire & Rubber Co (GT) vs Incyte Corporation (INCY) Price & Performance

Goodyear Tire & Rubber (GT) trades at $4.75, down 1.28% with bearish technical signals. The company faces significant challenges with a net loss of $1.72 billion in 2025 and negative profit margins, though valuation ratios appear attractive with P/E of 4.69 and P/B of 0.48. Recent earnings show mixed results with Q2 2026 beating expectations but still posting losses. Cash flow improved to $46 million in 2025, while debt remains elevated at $7.78 billion total.

The outlook remains challenging with ongoing restructuring efforts and volume pressures. Analyst consensus is mixed with 34.6% buy ratings but a $8.00 price target suggesting 68% upside. Key risks include execution of turnaround plan, competitive pressures, and high debt load. The stock's current valuation discounts much of the negativity, creating potential for recovery if management delivers on margin improvement targets.

Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.

The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.